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This study examined longitudinal, age-related and intra-individual variation in
Anti-Müllerian Hormone (AMH) in regular menstruating women and correlated the
hormonal levels to the antral follicle count (AFC). The impact of variations on an algorithm
for calculation of follitropin-dose for ovarian stimulation were also tested. The study
was carried out at a fertility clinic of a tertiary university hospital and had a prospective
trial design. Twenty-six healthy women not receiving infertility treatment aged 22 to
50 years participated. Blood sampling for hormonal analysis was done every fifth day
throughout three consecutive menstrual cycles, AFC was determined with 3-dimentional
ultrasound and AMH measured by different assays from Beckman Coulter, Roche and
Ansh Labs. Outcome measures were maximum and minimum difference in absolute and
relative terms for each study subject during the test-period, coefficient of variation (Cv)
for AMH for each cycle and cycle-day and correlation between AMH and AFC. The
impact from variable AMH levels on an algorithm calculating follitrophin-delta dose in
ovarian stimulation was explored. A significant longitudinal age-independent variation in
AMH-levels and coefficient of variation in cycles and cycle days was found. A strong
correlation between AMH-levels and AFC was confirmed and a case of significant
divergence between assays was seen. Variations in AMH had a significant impact on
an algorithm calculated dosage of gonadotrophins in ovarian stimulation. The finding
of a substantial longitudinal variation in AMH question one recording being sufficient in
quantifying gonadotrophins for ovarian stimulation, decision making and prognostication
related to infertility treatment and counseling. Occasionally, commercial assays may fail
to recognize specific AMH cleavage-products.
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INTRODUCTION
The serum concentration of Anti-Müllerian Hormone (AMH)
has gained widespread clinical use as a surrogate marker for
ovarian reserve. Currently, AMH measurements are used in
human fertility counseling (1), to predict age of menopause
(2), to diagnose polycystic ovarian syndrome (PCOS)(3, 4) and
to predict response to ovarian stimulation (OS) (5, 6). As
AMH levels may have major implications for clinical decisions
on whether or not to proceed with IVF, to change to egg
donation, to plan delay childbearing and attaining optimal
ovarian stimulation during treatment, AMH measurements
should be reliable and consistent.
The clinical use of AMH has to a large extent been
facilitated by a reported relatively stable serum concentration
during the menstrual cycle and an age-related decline bridging
several decades until being exhausted at menopause. However,
the interpretation of AMH results have previously been
complicated by the use of different assay-standards and assay-
characteristics (7–10). AMH undergoes proteolytic cleavage to
become biologically active and additional proteolytic processing
readily takes place (11). This processing, which may differ
between individuals, exposes new antigenic sites whichmay affect
measurements as well as AMH epitopes being masked by protein
interaction in the circulation (12). This is confirmed by recent
recognition of gender differences in AMH processing as western
blot analysis of immature human granulosa cells exposed several
other forms of AMH compared to those present in human fetal
testicular tissue (11).
Serum levels of AMH are significantly associated with the
number of antral follicles available for OS (13) and therefore
AMH concentrations are widely used to predict high and low
responders. A new recombinant follicle stimulating hormone
preparation (rFSH) has recently been introduced to the market
with an algorithm using serum level of AMH for the estimation
of an appropriate starting dose of exogenous FSH in OS (14, 15).
In light of these findings and the fact that several recent
studies have questioned the stability of AMH concentrations
across the menstrual cycle (16) as well as one study reporting
variation between cycles (17), the present study was initiated to
evaluate serum AMH concentrations in two age matched cohorts
of women during three consecutive cycles. Each blood sample
was measured by three different AMH assays; the Beckman
Coulter Gen II manual assay, the automated Roche Elecsys assay
and the pico AMH (24/32) from Ansh Lab, and the variability
was evaluated. Furthermore, a new algorithm launched for
quantifying the starting dose of a new rFSH (Rekovelle R©) for OS
was tested, looking into the consequences of variable AMHvalues
on the dosing dose.
SUBJECTS AND METHODS
This prospective observational study was conducted at the
Reproductive Medicine Centre, Skåne University Hospital
Malmö, Sweden (blood-sampling and hormonal assaying),
Herlev-Gentofte Hospital, University of Copenhagen, Denmark,
Laboratory of Reproductive Biology (LRB), Copenhagen
University Hospital, (Rigshospitalet), Denmark (computing
and interpretation of data) and Aarhus University Hospital,
Denmark (hormonal assaying). The Ethical Committee at Lund
University, Sweden, approved the study.
Study Subjects
Between November 2011 and June 2012, healthy, regularly
menstruating women aged 22–50 years were recruited, aged <30
years using recruitment posters at the hospital directed toward
hospital employees and medical or nursing students. Potential
study subjects answered a standardized questionnaire concerning
health, pregnancies, menstrual cycle length and received oral and
written information before signing a consent form. Inclusion
criteria were regular menstrual cycle in the range of 21–35 days,
no actual use of tobacco or hormonal medication including oral
contraceptives. Women with POCS were excluded.
In order to explore potentially age-related differences in
AMH-variations, a total of 26 healthy non-smoking volunteer
women, 16 below 30 years and 10 above 35 years fulfilling the
criteria were subsequently initiated participation in the study.
Two participants had 1 month’s halt between cycle 2 and 3 and
one women dropped out after fulfilling sampling in 2 cycles but
remained in the study population. For 24 of the study subjects,
measurements were performed in consecutive cycles.
Blood Sampling
The protocol included blood-sampling starting atmenstrual cycle
day 5 and continued every fifth day until the next menstrual
bleeding where after the same procedure was repeated for two
more cycles. Study subjects called the research team on the
first day of the menstrual bleeding for initiation and planning
of blood-sampling and vaginal ultrasound according to the
schedule indicated above. Each blood sample, consisting of 10mL
blood, was drawn into vacuumed vials containing gel through
a heparinized catheter inserted into a forearm vein. Within 2 h,
the samples were centrifuged at 2,000 g for 10min, and serum
from each individual was divided into 3 vials before being stored
at −20◦C thus completing three frozen vial-lines from the same
serum samples. When all samples from one study subject was
completed, the vials were moved and stored at −80◦ until each
of the samples were analyzed on three AMH ELISA platforms.
Assays
AMH is secreted as a non-active homodimer precursor united by
covalent bonds, which cleave bymeans of a proteolytic processing
to a biological active associated dimer. Binding of the associated
non-covalent complex to the receptor causes the N-terminal
to dissociate into a non-active N-terminal (pro-region) and an
active mature C-terminal (18). Detectable forms in serum would
thereby theoretically be;
1) non-active AMH-precursor dimer (covalent).
2) active pro-mature dimer (associated).
3) non-active N-fragment pro-region.
4) active mature C-terminal.
However, a new proteolytic cleavage take place around the
localization of amino acid 229 and also 451 (19, 20), giving
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rise to additional AMH-fragments like pro-mid-mature and
mid mature fragments. Cleavage of larger AMH-sections, like
the pro- and mature fragment, into sub-fragments may display
new epitopes targeted by the antibodies or potentially blinding
others, features which may impact on the ELISA-quantitation
of the hormone. Probably, processing the molecule is probably
individual and display time-related changes illustrated by the
finding of different forms of the AMH-molecule across the
menstrual cycle (9).
The samples were analyzed by three AMH ELISA assays
at different occasions and locations. During the first round
in 2012/2013, serum AMH was analyzed at Skåne University
Hospital, Malmø, Sweden, using the Gen II manual kits from
Beckman Coulter Inc., Marseille [30].
The lowest detectable level (LOD) distinguishable from zero
with 95% confidence is 0.7 pmol/l. Coefficient of variation (%)
of the Beckmann Coulter manual assay, calculated as standard
deviation (SD)/mean) ∗ 100, were 25% at 5.7 pmol/l and 12% at
52 pmol/l. All samples from one study subject were assayed in
one run.
For the automated Roche Elecsys assay the similar calculations
(%) were 1.9% at 6.3 pmol/L and 1.9% at 31.2 pmol/L The LOD
of the assay was set to 0.5 pmol/l.
The inter-assay coefficient of variation (%) was determined
by measuring daily replicates of controls in two levels in 36
consecutive workdays, with the result of 1.9% at both levels (6.3
and 31.2 pmol/l).
These two assays use 2 identical monoclonal antibodies
directed against epitope regions located within the mature and
pro-regions of the AMHmolecule (21, 22).
During the third comparison, the samples originally assayed
with Beckman Coulter 2012/2013 (Malmø) and refrozen were
analyzed at Ansh Labs, Texas in 2016. Here, a new ELISA
assay named pico AMH (24/32) with two monoclonal antibodies
directed toward epitope regions in pro and mature regions of
AMH was used. The antibodies used here are thus different
compared to the one used in the Beckman Coulter and Elecsys
Cobas assays. The LOD of the assay is 0.0086 pmol/l and total of
5.8% at 0.16 pmol/l and 4.4% at 2.7 pmol/L.
3D Ultrasound Images
Ultrasound analysis was performed using 4D-viewTM
software, version 9.1 (GE Medical systems, Zipf, Austria)
with Sonography-based Automated Volume Calculation
(SonoAVCTM) software by one observer (LJ) and calculations
were performed on multi-planar images showing the ovary in the
longitudinal, transverse and coronal planes. SonoAVC software
was used to calculate the number and size of antral follicles and
average diameter were determined and listed according to their
size. The SonoAVC report displays the automated measurements
of the mean diameter (relaxed sphere diameter), maximum
dimensions (x, y, z diameters) and volume of each object.
Most follicles, as hypo-echoic structures within a relatively
hyper-echoic ovarian stroma, can be analyzed using SonoAVC
software. However, to ensure that all follicles become recognized
the volume of the ovary was finally examined manually in
longitudinal and transverse planes to find follicles that had not
been detected by the SonoAVC software, or had been incorrectly
identified, and thereafter the follicle number was corrected.
The mean diameter and the number of follicles with a
diameter of 2.0–10.0mm were used for statistical analysis.
Statistics
Coefficient of variation (Cv), calculated as standard deviation
(SD)/mean, was used as measure to describe and compare
variations between groups. SD was highly dependent on mean
values whereas we saw lower dependence between Cv and mean
value.
The distributions of Cv were inspected visually and by
QQ-plots. Comparisons of Cv were performed using Repeated
measures of ANOVA. Two participants with all values below
detection limit in a cycle or at a cycle day were not included in
comparisons of Cv (#2 and #8). Additionally one participant (#6)
had low mean values of AMH including several measures below
detection limit and high Cv-values. This Participant was included
in calculations but to investigate whether the inclusion of this
participant changed the results sensitivity analyses excluding this
were performed.
Correlations between AMH and AFC-count were analyzed
using Spearman Rank correlation. Confidence interval for these
were calculated by a bootstrap method taking into account that
each participant had several measures.
For calculating the effect of mean level AMH on the variation,
one-way ANOVA was used.
All tests were two-sided. P-values below 0.05 were considered
statistical significant. All statistics were performed using R
version 3.3.3 (R Foundation of Statistical Computing, Vienna,
Austria).
RESULTS
Effect of Age on the Coefficient of Variation
No statistical difference in variation expressed by Cv was found
between the age-groups (Data not shown). As a consequence all
study-subjects were subsequently treated as one group.
Absolute and Relative Differences in Levels
of AMH During the Study Period for Each
Study-Subject
The minimum difference between the lowest and highest
measured level of AMH measured among the study-subjects
was found to be 3.9 pmol/L in absolute value during the
study period for Beckman Coulter, 4.4 pmol/L for Elecsys
Cobas and 0.5 pmol/L for the Ansh Labs assay (Table 1). The
corresponding maximum differences were 33.0, 31.4, and 45.5
pmol/L, respectively. The minimum and maximum relative
differences expressed in percentage for the study-subject with
the lowest and highest changes over 3 cycles (% relative
difference=highest- lowest value/lowest value∗100) was found to
be 60 and 446% for Beckman Coulter, 37 and 274% for Elecsys
Cobas and 42 and 728% for Ansh Labs assay (Table 1).
An overview of the intra-individual variation in AMH-levels
throughout the study period for a younger group of the study
population (below 30 years) is shown in Figure 1. The variation
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TABLE 1 | Absolute and relative differences was calculated in each woman of the
total population.
Beckman
coulter
Elecsys
cobas
AnshLab
Min diff (absolute value), pmol/L 3.9 4.4 0.5
Min diff, % (highest-lowest/
lowest * 100)
60 37 42
Max diff (absolute value), pmol/L 33.0 31.4 45.5
Max diff, % 446 274 728
The table provides the difference recorded in the individual woman with the highest and
lowest detected value.
in all three assays (median and range) for cycles is shown in
Figure 2 for women above 35 years and in Figure 3 for women
below 30 years.
Coefficient of Variation (Cv)
The individual variation in between cycles in the same patient
was 0.0–0.46 for Beckman Coulter, 0.0–0.57 for Elecsys Cobas
and 0.10–1.63 for Ansh Labs. The corresponding value for each
cycleday within the same cycle were 0.0–0.69 for Beckman
Coulter, 0.0–0.87 for Elecsys Cobas and 0.06–1.15 for Ansh
lab (Table 2). The mean and median values for CV were
similar indicating a symmetrical distribution (Table 2) with the
highest variation found for the Beckman Coulter assay (Table 2).
A graphical presentation of the individual variation for each
cycleday is given in Figure 4 and pr. cycle in Figure 5. This
displays graphically the huge dispersion in the recorded values
in the same study-subject in the course of three menstrual cycles,
as Cv is calculated from the equation standard deviation/mean.
Using Repeated measures ANOVA, differences in the Cv
across the cycle days were evident. Subsequent analysis revealed
these to be significant between measurements on cycle day
five and fifteen. Testing differences in between cycles revealed
significant altered variation in cycle one compared to cycle
two and three. Sensitivity analyses excluding one participant
with very low mean values and high Cv values did not change
conclusions (data not shown).
Effect of Mean Level AMH on the
Coefficient of Variation
The study subjects were stratified according to mean level of
AMH calculated from the Elecsys Cobas recordings, and divided
in low AMH (<10 pmol/L), medium AMH (10–20 pmol/L and
high AMH (>20 pmol/L). The group with the lowest AMH
recordings had a significant higher Cv tested with the Elecsys
Cobas and AnsLab assay but not with the Beckman Coulter assay
(Table 3).
Correlation Between AMH and Antral
Follicle Count
A strong correlation was found between AMH level and AFC-
count on cycle day 5, rs = 0.83 for Elecsys Cobas, 0.84 for
Beckman Coulter and 0.86 for Ansh Lab (Table 4).
A Case of Significant Discrepancy
Between Assays
One study subject displayed significant divergent readings
between the assays, with immeasurable AMH with Beckman
Coulter assay, values between 1.3 and 2.3 with Elecsys Cobas
assay to 30.8–60.5 pmol/l for picoAMH ELISA assay from Ansh
Labs (Figure 5). In all 3 cycles, her follicular phase estradiol and
luteal phase progesterone indicated complete normal ovulatory
cycles. Ultrasound detected antral follicle count at cycle day 5 of
each cycle were; 10 (cycle 1)−20 (cycle 2) and 23 (cycle 3).
The Calculated Effect of Varying AMH
Levels on the Follitropin Delta- Dose if
Treated According to Algorithm
Table 5 shows the differences in follitrophin delta dose calculated
from maximum and minimum recorded AMH values in the case
of using a single AMH recording and bodyweight as argument
in the dose-algorithm (14) of Rekovelle R©. The calculated
differences reveal no change in dose for women with a low
ovarian reserve with a fixed dose to as much as 3.67 mcg (50 IU)
(1 mcg= 13.7 IUI/L) in women with high ovarian reserve.
DISCUSSION
The major finding of this study is a substantial overall intra-
individual variation in AMH levels which to the best of
our knowledge has not previously been reported with sample
collection at 5 days intervals during three consecutive menstrual
cycles taking only normally menstruating woman into account.
The relative within-person biological variability ranged from 37
to 728% and by far exceeded the analytical variability of the three
assays that ranged from 1.9 to 25% which clearly demonstrate
a biological variation, which cannot be accounted for by assay
variability.
AMH is generally considered a reliable and stable marker
of ovarian function. Thus, in contrast to markers like FSH, no
recommendations regarding a particular cycle day for optimal
AMH assessment are currently recommended Furthermore, in
the clinical context, distinct AMH cut off concentrations are
often utilized to discriminate between normal and high or low
values. Concentrations of AMH in a range of 1.4–9.0 pmol/L have
been suggested to predict low response to hormonal stimulation
(22–24), while levels as high as 48.9 pmol/L (25) and as low
as 10.7 pmol/L (26) have been used to predict hyper response.
Age-dependent AMH-cutoff levels have also been recommended
as useful tools for predicting clear clinical outcome of assisted
reproductive technologies (27). The results of the present study
indicate that at least in normally menstruating women, over a
period of three consecutive cycles, the measured AMH level may
vary considerably. A recent randomized study (28) based on a
published algorithm (29) reported no improvement in adding
an AMH-reading for individualized hormone dosage compared
to a conventional regimen in controlled hormonal stimulation
for IVF, which reinforce this notion. The high variability in the
coefficient of variation in cycles and cycle-days supports a more
random regulation of the AMH-production most likely reflecting
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FIGURE 1 | Intra-individual variation in AMH levels in the 16 women below 30 years throughout the study period. Assay: Beckman Coulter Gen II.
FIGURE 2 | Median and range of AMH in three consecutive cycles with AMH measured cycle-day 5–10–15–20–25 at three analyzing platforms.
the effect of different factors regulating the number of follicles
with diameters of around 5 to 8 millimeters that predominantly
produce the AMHmeasured in circulation (13).
These data suggests the need to reevaluate the validity of
founding the design of an individualized ovarian stimulation
regimen on a single AMH measurement. Indeed, it is possible
that excessive reliance on a single AMH measurement could
expose the high responding patient to an increased risk of OHSS
in case where AMH-based algorithm is used for calculating
gonadotropin-dose for ovarian stimulation.
We found no difference in variation over time between the
age-groups, and the former reported age-dependent pattern (23)
of AMH-secretion could not be verified. The mean level of AMH
had a significant impact on the coefficient of variation with
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FIGURE 3 | Coefficient of variation (CV) per cycleday in three assay-groups.
TABLE 2 | Coefficient of variation per cycle-day and within cycle measured in three consecutive cycles.
Cycle day Beckman
coulter
COBAS Ansh lab P-value between
assays
5 0.14 (0.08)
0.15 (0.00–0.28)
0.18 (0.16)
0.16 (0.00–0.84)
0.21 (0.16)
0.18 (0.06–0.87)
0.11
10 0.19 (0.11)
0.18 (0.00–0.37)
0.20 (0.12)
0.18 (0.01–0.51)
0.22 (0.12)
0.21 (0.05–0.52)
0.63
15 0.29 (0.16)
0.26 (0.07–0.69)
0.23 (0.15)
0.18 (0.06–0.61)
0.25 (0.16)
0.19 (0.06–0.64)
0.016
20 0.23 (0.16)
0.21 (0.00–0.65)
0.25 (0.19)
0.21 (0.03–0.87)
0.22 (0.17)
0.18 (0.01–0.65)
0.67
25 0.20 (0.12)
0.21 (0.00–0.46)
0.20 (0.12)
0.19 (0.05–0.51)
0.21 (0.13)
0.20 (0.05–0.57)
0.90
30 0.10 (0.04)
0.11 (0.03–0.14)
0.07 (0.03)
0.08 (0.02–0.10) 0.11 (0.05)
0.08 (0.07–0.17)
0.16
Within cycle-day p-value (cycleday 30
excluded with only 6 recordings available)
0.003 0.11 0.69
CV Between three individual cycles
Cycle Beckman
coulter
COBAS Ansh lab P-value between
assays
1 0.18 (0.11)
0.17 (0.00–0.44)
0.15 (0.06)
0.14 (0.07–0.31)
0.17 (0.06)
0.16 (0.10–0.34)
0.025
2 0.19 (0.11
0.18 (0.00–0.46)
0.18 (0.11)
0.16 (0.05–0.57)
0.19 (0.09)
0.16 (0.09–0.52)
0.99
3 0.18 (0.08)
0.18 (0.00–0.30)
0.18 (0.08)
0.16 (0.05–0.36)
0.20 (0.09)
0.17 (0.05–0.37)
0.51
Within cycle p-value 0.70 0.10 0.31
Each cell shows values of CV as mean (SD) in the first row and in second roe in italics in median (range). Two participants were excluded from these analyses (#2, #8) due to immeasurable
levels of AMH.
highest Cv in the lowest group (AMH < 10 pmol/L) in the
recordings obtained with the Ansh Lab and Elecsys Cobas assays.
This effect was not seen in the Beckman Coulter assay which may
be explained by a wide dispersion of recordings in women with
low AMH, and unlike Ansh Lab and Elecsys Cobas displaying
measurable but very low values in some study-subjects, the
Beckman Coulter assay returned immeasurable values in the
same women which recordings were excluded from statistical
calculations (Table 3).
The Beckman-Coulter assay has been considered an
insufficiently precise AMH measurement technique compared
with the new automated Elecsys Cobas-assay (8, 24) although
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FIGURE 4 | Coefficient of variation (CV) per cycle in three assay-groups.
FIGURE 5 | A case of significant discrepancy between assays. The Beckman Coulter assay was not able to detect AMH and all readings have the value zero. Antral
follicle count and FSH recordings are added.
it uses identical monoclonal antibodies for measurement
(25, 26). However, this study shows that the intra and inter-cycle
variability was similar (Table 2). The third assay from Ansh labs
used two different antibodies addressing other epitopes, but
revealed the same variability over time in most situations. The
observed AMH variability seems more likely to be explained by
biologic variability. The highly significant correlation between
the AMH-readings (Figure 5) in the three assays reinforces
this conclusion. The level of AMH is different between the
three assays, which could reflect different standards used
for calibration alternatively the measure of different forms
of AMH.
The importance of the assay used is underlined by the reported
observations in one subject where both the Beckman Coulter
and the Elecsys Cobas assays revealed close to immeasurable
values of AMH. However, as measured by the picoAMH ELISA
assay, her ovarian reserve appeared to be extremely high
(40–60 pmol/l) (Figure 5). These findings were consistent with
ultrasound measurement of a corresponding number of antral
follicles at cycle day 5 of each of the 3 cycles (n = 10, 20,
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23). Moreover, the magnitude of estradiol in the follicular phase
and progesterone in the luteal phase indicated a normal ovarian
function. This result reflects the differences that may occur when
TABLE 3 | The effect of mean level AMH (Elecsys Cobas recordings) on the
coefficient of variation.
Low
(<10 pmol/L)
Medium
(10–20 pmol/L)
High
(>20 pmol/L)
P
Ansh lab 0.36 (0.14) 0.21 (0.05) 0.17 (0.04) 0.0006
Beckman coulter 0.28 (0.08) 0.25 (0.06) 0.21 (0.06) 0.15
Elecsys cobas 0.33 (0.16) 0.20 (0.05) 0.16 (0.04) 0.006
Mean (SD). P-values by one-way ANOVA.
TABLE 4 | Spearman’s Rank Correlation between AMH and AFC on menstrual
cycle day 5.
Rs (95% CI)*
Beckman coulter 0.83 (0.72–0.94)
Elecsys COBAS 0.83 (0.67–0.93)
AnshLab 0.85 (0.69–0.93)
*Confidence limits calculated by bootstrapping.
monoclonal antibodies recognizing different epitopes are used.
In this case protein interactions, with for instance follistatin, may
mask the epitopes recognized by the identical antibodies used in
the Beckman Coulter and Elecsys Cobas assay, which has been
reported to affect AMH signaling (12).
Similar discrepancies have been reported in women
approaching menopause where more than 95% of the AMH in
the circulation could be detected by the 24/32 (PicoAMH ELISA)
and 24/37 (Ansh labs) while only 36% could be detected by
Beckman Coulter gen II assay (27). This observation is probably
due to the amount of complex cleavage products in serum from
females.
The limitations of the study is a restricted number of study
subjects with a wide dispersion in AMH-recordings which
may influence the calculated variations. However, the number
of repeated samples with an average of 15 measurements
pr. individual throughout three consecutive menstrual cycles
exceeds the number of measurements reported by earlier
longitudinal studies. Additionally, blood samples from each
individual study subject was collected and assayed in one
run on three recognized platforms eliminating inter-assay bias
described in earlier reports (28). Furthermore, we focused
on normally menstruating women and not PCOS-women or
patients undergoing infertility treatment. Still, there is no reason
to believe that the relative intra-individual variation among
TABLE 5 | The calculated effect of varying AMH levels on the follitrophin delta-dose if treated according to algorithm.
Study
subject
Age (ys) Body-weight
(kg)
AMH Cobas
pmol/L max
AMH Cobas
pmol/L min
Dose rFSH
(mcg) max
Dose rFSH
(mcg) min
Difference in dose
rFSH (mcg) (max
AMH–minAMH)
Difference in dose
rFSH (IU/l) (max
AMH–minAMH)
1 41 64 16 7 12,0 12,0 0,0 0,0
2 50 63 1 1 12,0 12,0 0,0 0,0
3 40 80 32 18 12,0 9,66 2,34 31,9
4 39 50 11,6 6,8 12,00 12,00 0 0,0
5 46 70 17 8 12,0 12,0 0,00 0,0
6 45 57 3 0 12,0 12,0 0,0 0,0
7 41 65 12 3 12,0 12,0 0,0 0,0
8 42 80 2,4 1,3 12,0 12,0 0,0 0,0
9 37 55 15,3 8,7 12,0 12,00 0,0 0,0
10 42 59 9,9 3,5 12,0 12,0 0,0 0,0
11 25 64 40,9 28,9 7,66 6,33 1,33 18,1
12 29 65 45,4 33,1 7,00 6,66 0,34 4,6
13 25 65 20,9 11,1 12,00 9,66 2,34 31,9
14 29 70 33,7 22,4 10,66 7,66 3,00 40,9
15 27 75 3,1 0,7 12,0 12,0 0,0 0,0
16 25 62 46,3 24,5 8,0 6,33 1,67 22,8
17 26 58 33,9 17,6 10,0 6,33 3,67 50,0
18 27 66 22,6 9,1 12,0 9,33 2,67 36,4
19 27 57 10,3 6,0 12,0 12,0 0,0 0,0
20 22 69 26,9 14,6 12,0 9,00 3,00 40,9
21 26 62 14,9 8,7 12,0 11,66 0,34 4,6
22 25 83 42,1 20,8 12,0 8,33 3,67 50,0
23 26 61 23,2 10,1 12,0 8,33 3,67 50,0
24 28 63 61,7 35,5 7,00 6,33 0,67 9,1
25 24 69 62,6 31,3 8,33 7,00 1,33 18,1
26 28 58 21,6 13,9 12,0 8,66 3,34 45,5
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subfertile women, in general, will differ from the cohort on
women studies here. It should be emphasized that the Beckman
Coulter assay used in this study was a manual assay which later
has been replaced by automated technique displaying higher
precision (29).
In conclusion, AMH provides considerable information on
the ovarian reserve. However, a significant physiological intra-
individual biological variation is present questioning the clinical
validity of a single AMH-measurement in certain clinical settings.
These may include important counseling connected to IVF-
treatment or using AMH-based dosing algorithms in ovarian
stimulation. As documented, commercial assays will in some
individuals not be able to quantify their ovarian reserve due
to existence of different AMH- forms or interaction with other
proteins altering epitope exposure.
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